Algernon Pharmaceuticals EBIT

The latest EBIT for AGN.CN is $-1.6M as of May 2026. That compares with $-1.7M in the prior-year period — up 6.6% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Algernon Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AGN.CN's EBIT moved from $-1.7M to $-1.6M — a 6.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Algernon Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, AGN.CN currently prints $-1.6M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Algernon Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-1.6M for AGN.CN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting AGN.CN's EBIT ($-1.6M), review year-over-year change from $-1.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.